We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
CRSP is expected to beat Q4 earnings numbers after topping expectations in three of the last four quarters.
CRSP's revenues include grants and collaboration income tied to Casgevy sales with partner Vertex.
Casgevy is the company's only marketed product, approved for SCD and TDT in the United States and Europe.
We expect CRISPR Therapeutics (CRSP - Free Report) to surpass expectations when it reports fourth-quarter and full-year 2025 results. The company’s earnings beat estimates by 11.36% in the last reported quarter.
The Zacks Consensus Estimate for quarterly sales is pegged at $4.00 million, while that for earnings is pinned at a loss of $1.15 per share.
Factors Shaping CRSP’s Upcoming Results
CRISPR Therapeutics’ top line currently includes grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals (VRTX - Free Report) .
CRSP and partner VRTX’s one-shot gene therapy, Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) — across the United States and Europe. This therapy is the first and currently the only marketed product in the company’s portfolio.
Per the collaboration terms, Vertex leads global development, manufacturing and commercialization, and splits program costs and profits worldwide in a 60:40 ratio with the company. CRISPR Therapeutics is currently recording its share of Casgevy's sales as an adjustment to collaboration expenses (net). Casgevy sales have been rising in recent quarters, which is likely to have led to an improvement in collaboration expense for the to-be-reported quarter.
Investors will likely be interested in getting more updates on the global regulatory submissions, planned for the first half of 2026, seeking label expansion for Casgevy in patients aged 5-11 years with SCD and TDT. For the FDA submission, Vertex intends to use the Commissioner’s National Priority Voucher to significantly cut down the review period to just 1-2 months.
CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. One such candidate is zugo-cel (formerly CTX112), which is being evaluated across separate early-stage studies — one for CD19-positive B-cell malignancies and another for systemic lupus erythematosus (SLE), systemic sclerosis and inflammatory myositis in autoimmune disorders.
Apart from zugo-cel, CRISPR Therapeutics is currently studying its first two in-vivo candidates, CTX310 and CTX320, in separate phase I clinical studies targeting ANGPTL3 and lipoprotein(a), respectively. The company intends to further expand its in-vivo pipeline with two more programs, CTX340 (for refractory hypertension) and CTX450 (for acute hepatic porphyria), which it plans to advance to clinical development before this year’s end.
CRSP’s Earnings Surprise History
The biotech firm’s performance has been decent over the past four quarters. Its earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 15.23%.
In the past year, CRISPR’s shares have surged over 28% compared with the industry’s15% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for CRSP
Our proven model predicts an earnings beat for CRISPR Therapeutics this time around. The combinationofa positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: CRISPR Therapeutics has an Earnings ESP of +15.85%. The Most Accurate Estimate stands at a loss of 97 cents per share, while the Zacks Consensus Estimate is pegged at a loss of $1.15.
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +80.95% and a Zacks Rank #1 at present.
Shares of CSTL have rallied more than 37% in the past year. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. Castle Biosciences delivered an average surprise of 66.11%.
Moderna (MRNA - Free Report) has an Earnings ESP of +4.86% and a Zacks Rank #3 at present.
Shares of MRNA have risen over 16% in the past year. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.45%. Moderna is scheduled to report fourth-quarter results on Feb. 13.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
Key Takeaways
We expect CRISPR Therapeutics (CRSP - Free Report) to surpass expectations when it reports fourth-quarter and full-year 2025 results. The company’s earnings beat estimates by 11.36% in the last reported quarter.
The Zacks Consensus Estimate for quarterly sales is pegged at $4.00 million, while that for earnings is pinned at a loss of $1.15 per share.
Factors Shaping CRSP’s Upcoming Results
CRISPR Therapeutics’ top line currently includes grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals (VRTX - Free Report) .
CRSP and partner VRTX’s one-shot gene therapy, Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) — across the United States and Europe. This therapy is the first and currently the only marketed product in the company’s portfolio.
Per the collaboration terms, Vertex leads global development, manufacturing and commercialization, and splits program costs and profits worldwide in a 60:40 ratio with the company. CRISPR Therapeutics is currently recording its share of Casgevy's sales as an adjustment to collaboration expenses (net). Casgevy sales have been rising in recent quarters, which is likely to have led to an improvement in collaboration expense for the to-be-reported quarter.
Investors will likely be interested in getting more updates on the global regulatory submissions, planned for the first half of 2026, seeking label expansion for Casgevy in patients aged 5-11 years with SCD and TDT. For the FDA submission, Vertex intends to use the Commissioner’s National Priority Voucher to significantly cut down the review period to just 1-2 months.
CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. One such candidate is zugo-cel (formerly CTX112), which is being evaluated across separate early-stage studies — one for CD19-positive B-cell malignancies and another for systemic lupus erythematosus (SLE), systemic sclerosis and inflammatory myositis in autoimmune disorders.
Apart from zugo-cel, CRISPR Therapeutics is currently studying its first two in-vivo candidates, CTX310 and CTX320, in separate phase I clinical studies targeting ANGPTL3 and lipoprotein(a), respectively. The company intends to further expand its in-vivo pipeline with two more programs, CTX340 (for refractory hypertension) and CTX450 (for acute hepatic porphyria), which it plans to advance to clinical development before this year’s end.
CRSP’s Earnings Surprise History
The biotech firm’s performance has been decent over the past four quarters. Its earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 15.23%.
CRISPR Therapeutics AG Price and EPS Surprise
CRISPR Therapeutics AG price-eps-surprise | CRISPR Therapeutics AG Quote
In the past year, CRISPR’s shares have surged over 28% compared with the industry’s15% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for CRSP
Our proven model predicts an earnings beat for CRISPR Therapeutics this time around. The combinationofa positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: CRISPR Therapeutics has an Earnings ESP of +15.85%. The Most Accurate Estimate stands at a loss of 97 cents per share, while the Zacks Consensus Estimate is pegged at a loss of $1.15.
Zacks Rank: CRSP currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks With Favorable Combinations
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +80.95% and a Zacks Rank #1 at present.
Shares of CSTL have rallied more than 37% in the past year. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. Castle Biosciences delivered an average surprise of 66.11%.
Moderna (MRNA - Free Report) has an Earnings ESP of +4.86% and a Zacks Rank #3 at present.
Shares of MRNA have risen over 16% in the past year. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.45%. Moderna is scheduled to report fourth-quarter results on Feb. 13.